Study of new treatments for colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with colorectal adenocarcinoma (a type of colon or rectal cancer).
- You can provide a tumor sample that was collected as part of your regular care.
- Your cancer has tumors that can be measured on scans (at least one measurable tumor).
- You are able to carry out daily activities without help or with some help (ECOG score 0 or 1).
- You have not received any systemic therapy for metastatic colorectal cancer, except for adjuvant chemotherapy completed more than 6 months ago.
- Your cancer is pMMR/MSS type (not MSI-H).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people whose colorectal cancer has spread to other parts of the body but not to the liver. The goal is to see if this combination works better than current treatments for this specific type of cancer.
This trial is for people with advanced colorectal cancer that has stopped responding to first-line treatment. It tests a combination of chemotherapy, a targeted therapy, and an investigational drug to see if it can help slow the cancer's growth.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new drug called LPM6690176 combined with chemotherapy and Avastin (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. It may be an option for those who haven't had treatment for their advanced cancer or have already tried one line of therapy.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.